Familial Cancer

, Volume 17, Issue 2, pp 275–280 | Cite as

Pancreatic neuroendocrine tumor in a patient with a TSC1 variant: case report and review of the literature

  • Parisa Mortaji
  • Katherine T. Morris
  • Von Samedi
  • Steven Eberhardt
  • Shawnia Ryan
Review

Abstract

The majority of pancreatic neuroendocrine tumors (PNETs) are sporadic while 10–15% are attributable to one of several familial cancer syndromes. Hereditary forms are more commonly associated with Multiple Endocrine Neoplasia Type I and von Hippel Lindau Syndrome. However, patients with Tuberous sclerosis complex also have an increased incidence of PNETs. More often this has been reported in patients with TSC2 variants. In this case report, we summarize the literature regarding PNETs associated with Tuberous sclerosis complex, as well as present a case of a patient with a TSC1 variant and a PNET. This case highlights the association of TSC1 gene variants with these tumors and emphasizes the importance of considering such diagnoses in this patient population.

Keywords

Hereditary cancer syndromes Pancreatic neuroendocrine tumors TSC1 Tuberous sclerosis complex 

Notes

Compliance with ethical standards

Conflict of interest

The authors do not identify any conflicts of interest.

References

  1. 1.
    Northrup H, Koenig M, Pearson D, Au K (2015) Tuberous sclerosis complex. In: GeneReviews at GeneTests: medical genetics information resource, University of Washington, Seattle, pp 1997–2016. https://www.ncbi.nlm.nih.gov/books/NBK1220/
  2. 2.
    Santos L, Brcic I, Unterweger G, Riddell R, Langner C (2015) Hamartomatous polyposis in tuberous sclerosis complex: case report and review of the literature. Pathol-Res Pract 211(12):1025–1029CrossRefPubMedGoogle Scholar
  3. 3.
    Kumar V, Abbas A, Aster J (2015) Tuberous sclerosis complex. In: Robbins and cotran pathologic basis of disease 9th edn. Elsevier, PhiladelphiaGoogle Scholar
  4. 4.
    Lodish MB, Stratakis CA (2010) Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes. Best Pract Res Clin Endocrinol Metab 24(3):439–449CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Northrup H, Krueger DA (2013) International tuberous sclerosis complex consensus group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol 49:243–254CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sancak O, Nellist M, Goedblood M, Elfferich P, Wouters C, Maat-Kievit A, Zonnenberg B, Verhoef S, Halley D, van den Ouweland A (2005) Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur J Hum Genet 13:731–741CrossRefPubMedGoogle Scholar
  7. 7.
    Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ (2001) Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1 disease in multiple organs. Am J Hum Genet 68:64–80CrossRefPubMedGoogle Scholar
  8. 8.
    Jansen FE, Braams O, Vincken KL, Algra A, Anbeek P, Jennekens-Schinkel A, Halley D, Zonnenberg BA, van den Ouweland A, van Huffelen AC, van Nieuwenhuizen O, Nellist M (2008) Overlapping neurologic and cognitive phenotypes in patients with TSC1 or TSC2 mutations. Neurology 70:908–915CrossRefPubMedGoogle Scholar
  9. 9.
    Jansen AC, Sancak O, D’Agostino MD, Badhwar A, Roberts P, Gobbi G, Wilkinson R, Melanson D, Tampieri D, Koenekoop R, Gans M, Maat-Kievit A, Goedbloed M, van den Ouweland AM, Nellist M, Pandolfo M, McQueen M, Sims K, Thiele EA, Dubeau F, Andermann F, Kwiatkowski DJ, Halley DJ, Andermann E (2006) Unusually mild tuberous sclerosis phenotype is associated with TSC2 R905Q mutation. Ann Neurol 60:528–539CrossRefPubMedGoogle Scholar
  10. 10.
    Kothare SV, Singh K, Chalifourx JR, Staley BA, Weiner HL, Menzer K, Devinsky O (2014) Severity of manifestations in tuberous sclerosis complex in relation to genotype. Epilepsia 55(7):1025–1029CrossRefPubMedGoogle Scholar
  11. 11.
    Rosset C, Netto CB, Ashton-Prolla P (2017) TSC1 and TSC2 gene mutations and their implications for treatment in tuberous sclerosis complex: a review. Genet Mol Biol. doi: 10.1590/1678-4685-gmb-2015-0321 PubMedPubMedCentralGoogle Scholar
  12. 12.
    Lewis JC, Thomas HV, Murphy KC, Sampson JR (2004) Genotype and psychological phenotype in tuberous sclerosis. J Med Genet 41:203–207CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Numis AL, Major P, Montenegro MA, Muzykewica DA, Pulsifer MB, Thiele EA (2011) Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex. Neurology 76:981–987CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Al-Saleem T, Wessner LL, Scheithauer BW, Patterson K, Roach ES, Dreyer SJ, Fujikawa K, Bjornsson J, Bernstein J, Henske EP (1998) Malignant tumors of the kidney, brain and soft tissues in children and young adults with the tuberous sclerosis complex. Cancer 83:2016–2208CrossRefGoogle Scholar
  15. 15.
    Yang P, Cornejo KM, Sadow PM, Cheng L, Wang M, Xiao Y, Jiang Z, Oliva E, Jozwiak S, Nussbaum RL, Feldman AS, Paul E, Thiele EA, Yu JJ, Henske EP, Kwiatkowski DJ, Young RH, Wu CL (2014) Renal cell carcinoma in tuberous sclerosis complex. Am J Surg Pathol 38:895–909CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Larson AM, Hedgire SS, Deshpande V, Stemmer-Rachamimov AO, Harisinghani MG, Ferrone CR, Shah U, Thiele EA (2012) Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex. Clin Genet 82:558–563CrossRefPubMedGoogle Scholar
  17. 17.
    Diaz Diaz D, Ibarrola C, Gomez-Sanz R, Perez Hurtado B, Salazar Tabares J, Colina Ruizdelgado F (2012) Neuroendocrine tumor of the pancreas in a patient with tuberous sclerosis: a case report and review of the literature. Int J Surg Pathol 20(4):390–395CrossRefPubMedGoogle Scholar
  18. 18.
    Gustafson S, Eng S (2008) Patient with multifocal renal cell carcinoma, pancreatic neuroendocrine tumor and TSC1 Q343X mutation, TSC2 SNP and PTEN c.210-7 ~ 3del5 http://www.ashg.org/2008meeting/abstracts/fulltext/f20544.htm. Accessed 14 April 2017
  19. 19.
    Krueger DA, Northrup H (2013) Tuberous sclerosis complex surveillance and management of the 2012 International tuberous sclerosis complex consensus conference. Pediatr Neurol 49(4):255–265CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Dworakowska D, Grossman AB (2009) Are neuroendocrine tumors a feature of tuberous sclerosis? A systematic review. Endocr Relat Cancer 16(1):45–58CrossRefPubMedGoogle Scholar
  21. 21.
    Arva NC, Pappas JG, Bhatla T, Raetz EA, Macari M, Ginsburg HB, Hajdu CH (2012) Well differentiated pancreatic neuroendocrine carcinoma in tuberous sclerosis: case report and review of the literature. Am J Surg Pathol 36(1):149–153CrossRefPubMedGoogle Scholar
  22. 22.
    Laplante M, Sabatini DM (2012) mTOR signaling in growth and disease. Cell 149(2):274–293CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Cinglarlini SS, Bonomi M, Corbo V, Scarpa A, Tortora (2012) Profiling mTOR pathway in neuroendocrine tumors. Target Oncol 7(3):183–188CrossRefGoogle Scholar
  24. 24.
    Koc G, Sugimoto S, Kuperman R, Kammen B, Karakas SP (2016) Pancreatic tumors in children and young adults with tuberous sclerosis complex. Pediatr Radiol 47:39–45CrossRefPubMedGoogle Scholar
  25. 25.
    Bombardierei R, Moavero R, Roberto D, Cerminara C, Curatolo P (2013) Pancreatic Neuroendocrine tumor in a child with a tuberous sclerosis complex 2 (TSC2) mutation. Endocr Pract 19(5):e124–e128CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2017

Authors and Affiliations

  1. 1.University of New Mexico School of MedicineAlbuquerqueUSA
  2. 2.Department of SurgeryUniversity of Oklahoma Health Sciences CenterOklahoma CityUSA
  3. 3.Department of PathologyUniversity of New Mexico School of MedicineAlbuquerqueUSA
  4. 4.Department of RadiologyUniversity of New Mexico School of MedicineAlbuquerqueUSA
  5. 5.The University of New Mexico Comprehensive Cancer CenterAlbuquerqueUSA

Personalised recommendations